Back to discover
Disease

Barrett Esophagus

Late-stage therapeutic developmentEmerging research
MeSHBarrett Esophagus
2
Publications
13
Clinical trials
2015
Latest publication
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this disease.

What's happening now

An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.

Executive briefingUpdating summary…Momentum: Low
Key developments
  • 1 clinical trial expected to report results, the earliest in Q3 2027.
Upcoming Milestones
Major developments
Major trial resultsHigh impact
Effect of Aspirin on Biomarkers of Barrett's Esophagus After Successful Eradication of Barrett's Esophagus With Radiofrequency Ablation
Results posted2026-06-17
Upcoming trial readoutImportant
Obeticholic Acid for Prevention in Barrett's Esophagus
Results expected Q3 20272026-05-13
Clinical Milestones3View
Results posted 1
Results expected 1
Recently completed 1
Activity timeline3

Clinical trials

8 sponsors · 0 new · 1 completed in the last 12 months (net +0)

The current development programme across all trial phases.

Clinical programme
13
All trials
2
Active
1
Late-stage
6
Completed
Recruiting

Obeticholic Acid for Prevention in Barrett's Esophagus

Phase 2 · Recruiting · National Cancer Institute (NCI)
Recently completed

Pilot Study of GCC Agonists to Identify a Cyclic-GMP Signal in Duodenal Tissue of Volunteers

Phase 1 · Completed · University of Wisconsin, Madison

Molecular Fluorescence Endoscopy for the Detection of (Pre)Malignant Lesions in Barrett's Esophagus Using a Fluorescent Tracer 'EMI-137' Targeting c-Met: a Single-center Feasibility and Safety Study

Phase 1 · Completed · University Medical Center Groningen

Phase I In-vivo Study of Multiplexed Heptapeptides for Detection of Neoplasia in the Esophagus

Phase 1 · Completed · University of Michigan

Clinical Study of Ursodeoxycholic Acid in Barrett's Patients

Phase 2 · Completed · National Cancer Institute (NCI)

Randomized Double Blind Placebo Controlled Trial of Barrett's Esophagus Chemoprevention With Metformin

Phase 2 · Completed · National Cancer Institute (NCI)

Randomized, Double-Blinded Phase II Trial of Esomeprazole Versus Esomeprazole + Two Doses of Aspirin in Barrett's Esophagus Patients

Phase 2 · Completed · National Cancer Institute (NCI)

Research activity

2 papers

Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.

Publications over time
20142015
Major themes1
  • Barrett Esophagus1
Leading journals2
  • Endoscopy1
  • Gut1
Leading researchers8
  • Bhandari P2
  • Amato A1
  • Ang Y1
  • Attwood S1
  • Berr F1
  • Bialek A1
  • Bird-Lieberman E1
  • Conio M1
Affiliations (unnormalised)6
  • Bispebjerg Hospital1
  • Cliniques universitaires St-Luc1
  • Erasmus Medical Center1
  • Gedyt Endoscopy Center1
  • Institute for Pathology1
  • Institute of Pathology1

Reference

Authoritative identity, definition & identifiers.

Defined in MeSH

A condition with damage to the lining of the lower ESOPHAGUS resulting from chronic acid reflux (ESOPHAGITIS, REFLUX). Through the process of metaplasia, the squamous cells are replaced by a columnar epithelium with cells resembling those of the INTESTINE or the salmon-pink mucosa of the STOMACH. Barrett's columnar epithelium is a marker for severe reflux and precursor to ADENOCARCINOMA of the esophagus.

Identifiers
MeSHBarrett Esophagus
References & data sources
  • Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
  • Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
  • Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
  • Related entities are derived from literature co-mention (studied together) — associative, not causal.